Harte Hanks (HHS)
(Delayed Data from NSDQ)
$3.41 USD
0.00 (0.00%)
Updated Aug 5, 2025 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HHS 3.41 0.00(0.00%)
Will HHS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HHS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HHS
Harte-Hanks (HHS) Q3 Earnings and Revenues Top Estimates
Integral Ad Science (IAS) Q3 Earnings Top Estimates
HHS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harte-Hanks (HHS) Flat As Market Gains: What You Should Know
Harte-Hanks (HHS) Stock Moves -0.84%: What You Should Know
Harte-Hanks (HHS) Stock Falls Amid Market Uptick: What Investors Need to Know
Other News for HHS
Emergent BioSolutions signs contract modification award for CNJ-016
Trump-Administration's Health Agency Overstepped Authority, Reorganization Unlawful: Court
Harte Hanks announces president appointment; shares down
Harte Hanks appoints David Fisher as president
Harte Hanks extends line of credit with Texas Capital Bank